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Summary 
Speed and selectivity of hepatocyte invasion by malaria sporozoites have suggested a receptor- 
mediated mechanism  and  the  specific  interaction  of the  circumsporozoite  (CS)  protein  with 
liver-specific heparan sulfate proteoglycans (HSPGs) has been implicated in the targeting to the 
liver. Here we show that the CS protein interacts not only with cell surface heparan sulfate, but 
also with the low density lipoprotein receptor-related protein (LRP). Binding of 125I-CS protein 
to purified LRP occurs with a K d of 4.9 nM and can be inhibited by the receptor-associated 
protein (RAP). Blockage of L1KP by RAP or anti-L1KP antibodies on heparan sulfate-deficient 
CliO cells results in more than 90% inhibition of binding and endocytosis of recombinant CS 
protein.  Conversely, blockage  or enzymatic  removal of the  cell  surface  heparan sulfate  from 
LRP-deficient embryonic mouse fibroblasts yields the same degree of inhibition.  Heparinase- 
pretreatment  of LRP-deficient  fibroblasts  or  blockage  of LRP  on  heparan  sulfate-deficient 
CHO cells by RAP, lactoferrin, or anti-L1LP antibodies reduces Plasmodiurn  berghei invasion by 
60-70%. Parasite development in heparinase-pretreated HepG2 cells is inhibited by 65% when 
RAP is present during sporozoite invasion. These findings suggest that malaria sporozoites uti- 
lize the interaction of the CS protein with HSPGs and L1KP as the major mechanism for host 
cell invasion. 
M 
inutes  after  introduction  into  the  host,  malaria 
sporozoites  invade  hepatocytes  where  they  subse- 
quently  develop  into  large  numbers  of erythrocyte-infec- 
tive merozoites.  The  entire  surface  of these  sporozoites is 
covered by the  circumsporozoite  (CS) 1 protein  and it has 
therefore  been  proposed  that  this  protein  mediates  the 
rapid  and  selective  invasion  of hepatocytes  (reviewed  in 
reference  1).  The  CS protein  has been  shown to  interact 
specifically with fiver heparan  sulfate proteoglycans (HSPGs) 
(2-4) and CS protein is selectively cleared from the blood- 
stream by the fiver (5, 6), most likely mediated by an inter- 
action between clusters of basic amino acids in the CS pro- 
tein  and  negatively  charged  sulfate  groups  in  heparan 
sulfate  (6). The  selectivity  of  the  CS  protein  for  liver 
HSPGs may depend on their unusually high overall degree 
of sulfation  compared  to  the  heparan  sulfate  chains  from 
other  tissues,  in  particular  the  vascular  endothelium  (7). 
Therefore,  the selective  targeting of recombinant CS pro- 
1Abbreviations used in this  paper: CS, circumsporozite; EEF, exoerythrocytic 
form; GST, glutathione-S-transferase; HSPGs, liver heparan sulfate pro- 
teoglycans; LDLP., low density lipoprotein receptor; LP.P, LDL recep- 
tor-related protein; MEF, mouse embryonic fibroblast; RAP, receptor- 
associated protein; TRAP, thrombospondin-related adhesive protein, 
tein to the liver is likely to be mediated by recognition of 
heparin-like  oligosaccharides  in  hepatocyte  HSPGs.  The 
events of sporozoite invasion, however, appear to use addi- 
tional receptor-ligand interactions,  since Plasmodium  berghei 
sporozoite invasion in vitro can also occur in the absence of 
cell surface heparan sulfate  (8). 
A  variety  of host  substances,  such  as  apolipoprotein  E 
(apo  E)-enriched  chylomicron  remnants,  are  also rapidly 
removed from the  blood circulation by the  liver and  this 
process can be inhibited by lactoferrin (9-15). The intrave- 
nous administration  of heparinase inhibits  the  clearance  of 
lipoprotein  remnants  from  the  plasma  and  HSPGs  have 
therefore been implicated in the initial trapping mechanism 
of the liver (13).  The subsequent endocytic uptake of the 
remnants into hepatocytes (15) is mediated by the low den- 
sity lipoprotein receptor (LDLR) in concert with the struc- 
turally  related  LDL receptor-related  protein  (LRP),  both 
members of a family of endocytosis receptors  (reviewed in 
reference  16,  17).  The  binding  of all  known  ligands  of 
LRP is inhibited by the 39-kD receptor-associated protein 
(RAP)  (18,  19). Cell surface HSPGs play a synergistic role 
in the binding and internalization  of various LRP ligands. 
For example, HSPGs are required for the hepatic lipase- or 
lipoprotein  lipase-mediated  enhanced  binding and  uptake 
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tate  the  LRP-mediated  endocytosis  of lactoferrin  (•4)  and 
apo E-enriched remnant lipoproteins  (12, 25). 
A  recent report  suggests  the  involvement of lipoprotein 
clearance  pathways  of the  host in  malaria  sporozoite  inva- 
sion of the liver. Apo E-enriched  [3-VLDL inhibit the de- 
velopment of P.  berghei sporozoites in HepG2 cells in vitro 
and LDLR  knock-out  mice  maintained  on  a  high  fat  diet 
are less  susceptible  to infection by Plasmodium  yoelii sporo- 
zoites  (26).  It appears,  therefore,  that remnant lipoproteins 
compete  in vitro  and in vivo for the  same  binding sites  as 
the CS protein and malaria sporozoites.  The similarities be- 
tween  the  targeting of malaria  sporozoites  to  the  liver and 
the  liver-mediated  clearance  of  chylomicron  remnants 
from the bloodstream prompted us to investigate the possi- 
bility that LRP  or the LDLR play a  role in sporozoite  ad- 
hesion and invasion of hepatocytes.  Our results suggest that 
the dual HSPG and LILP receptor system functions also as a 
mediator of sporozoite invasion. 
Materials and Methods 
Materials.  BSA  (fraction  V),  heparin  (grade  I),  chloroquine, 
lactoferrin  (from bovine colostrum)  and RPMI  1640 were from 
Sigma  (St.  Louis,  MO).  Heparinase  and heparitinase  were from 
Seikagaku  (Rockville,  MD),  FCS  from  Hyclone  (Logan,  UT), 
IODO-GEN from Pierce (Rockford, IL),  125I-iodine from Amer- 
sham  Corp.  (Arlington  Heights,  IL),  Sephadex  G-25  columns 
from Isolab  (Akron, OH), heparin-Sepharose from Pharmacia (Pis- 
cataway, NJ), 96-well (P,.emovawell) tissue culture plates from Dy- 
natech  Laboratories,  Inc.  (Chantilly,  VA),  12-well  plates  form 
Coming (Coming, NY), and 8-well Lab-Tek tissue culture slides 
from Nunc (Naperville, IL). The silver enhancement reagent was 
from Amersham. 
Recombinant Proteins.  Escherichia  coli-derived Ptasmodium  falciparum 
CS proteins CS27IVC-His  6 (AA 27-123[NANPNVDP]3 [NANP]21 
300-411)  contains region I and II-plus as well as the complete re- 
peat region,  CSFZ(Cys)-Hiss  (AA 27-123[NANP]300-411)  also 
contains  region  I  and  region  II-plus,  but  only  one  repeat  were 
kindly  provided  by  Dr.  Bela  Takacs  (F.  Hoffmann-La  Roche 
Ltd.,  Basel,  Switzerland)  and  the  yeast-derived  Falc-1  (Chiton 
Corporation,  Emeryville,  CA),  which  terminates  at  amino  acid 
348  and therefore lacks  region  II-plus  (2). LRP was  a generous 
gift  of Dr.  Dudley  K.  Strickland  (American  Red  Cross,  Rock- 
ville,  MD)  (27).  The  recombinant  Salmonella japonicum  glu- 
tathione-S-transferase  (GST)-RAP  fusion  protein  was  kindly 
provided by Dr. Joachim Herz  (University of Texas Southwest- 
ern Medical School, Dallas, TX)  (19). 
Antibodies.  The  repeat  region  of the  P. falciparum  CS  con- 
structs was detected by mAb 2A10 (28) and the repeats of the P. 
berghei CS protein by the mAb 3D11  (29).  The mAb 2E6 is di- 
rected against a heat shock protein in P.  berghei EEF (30). DAMP 
(Molecular Probes, Eugene, OR) as a marker for acidic organelles 
(31) was  labeled with  anti-DNP-KLH  conjugated  to  Texas  red 
(anti-DNP-TX;  Molecular  Probes).  Affinity-purified  polyclonal 
rabbit anti-L1LP IgG antibodies  (rb 777;  designated here as anti- 
LP,.P), generated  against  purified  human placental  LRP,  were  a 
kind gift of Dr. Dudley K.  Strickland (18).  Goat anti-mouse IgG 
conjugated  to  FITC  (GAM-FITC)  or  to  peroxidase  were  from 
Boehringer (Indianapolis, IN) and goat anti-mouse IgG gold 10 nm 
(GAM 10) and protein A gold 10 nm (PAG 10) from Amersham. 
Cell Lines and Culture.  The  human hepatocellular  carcinoma 
cell line HepG2 (ATCC HB 8065) was from the American Type 
Culture Collection (Rockville, MD). The wild-wpe  (CHO-K1) 
and mutant CHO  (psgA) cells were kindly provided by Dr. Jef- 
frey  D.  Esko  (University  of Mabama  at  Birmingham).  Mutant 
CHO psgA cells have a defect in xyloside-transferase, and express 
only the  core  protein  of proteoglycans  (32).  Derivatives from a 
wild-type mouse embryonic fibroblast  (MEF)  cell line that were 
deficient in LRP, the LDL receptor or both receptors (33) were a 
generous gift  of Dr. Joachim Herz  (University  of Texas  South- 
western Medical School, Dallas, TX). 
Solid Phase Binding Assay.  The  CS  construct  CS27IVC  was 
iodinated and affinity-purified according to (6). Removawell mi- 
crotiter plates were coated overnight at 4°C with 100 Ixl per well 
of purified LRP  (6 b~g/ml) or BSA (10 mg/ml) in TBS  (50 mM 
Tris, pH 7.4,  containing 150 mM NaC1 and 5 mM CaC12) (34). 
The wells were then blocked for  1 h  at room temperature with 
10 mg/ml BSA in TBS.  125I-labeled CS27IVC at a final concen- 
tration of 2 nM in TBS was added to the wells in the presence of 
0,  0.02,  0.2,  2,  20,  or  200  nM  unlabeled  affinity-purified 
CS27IVC or GST-RAP. Aliquots of each radiolabeled stock so- 
lution  were  counted  to  determine  the  total  cpm  added to  each 
well.  After an overnight incubation at 4°C, the wells were washed 
and the amount  of bound  ~2sI-CS27IVC per well  measured by 
liquid  scintillation  counting.  The  data  were  analyzed  using  the 
program LIGAND  (35) to determine the curve with the best fit 
for  the  calculation  of the  dissociation  (Ka) and  inhibition  (Ki) 
constants. 
Cell Binding Assay.  HepG2, MEF or CHO cells were seeded 
into  Removawell  microtiter  plates  and  incubated  in  assay me- 
dium (P,.PMI containing 0.5% FCS) for 30 rain at 4°C. Iodinated 
CS27IVC was then added to the cells at a final concentration of 4 
nM at 4°C according to Williams et al.  (34).  Some of the wells 
were preincubated either for 3 h at 37°C with 0-10 mU/ml hep- 
arinase  or for  30  min  at  4°C  with  0-100  Ixg/ml  heparin,  0-10 
lxg/ml anti-LRP  or control IgG (anti-ubiquitin  rabbit  IgG; Boeh- 
ringer), 0-150 I~g/ml GST-R_AP or 0--400 txg/rnl lactoferrin be- 
fore addition of iodinated CS27IVC at a final concentration of 4 
nM and the incubation continued for 2 h at 4°C. The amount of 
cell surface-bound 125I-CS27IVC was measured by liquid scintil- 
lation counting.  To determine the affinity of the binding of the 
CS protein to the cell surface,  HepG2 cells were incubated with 
either 0,  0.04,  0.4,  4,  40,  or 400 n_M unlabeled affinity-purified 
CS27IVC or GST-RAP for 30 min at 4°C. 12sI-CS27IVC (4 nM 
final  concentration)  was  then  added  for  2  h  at  4°C  and  the 
amount of cell surface-bound ligand measured as above. Aliquots 
of each  radiolabeled  stock  solution  were  counted  to  determine 
the total cpm added to each well. 
Endocytosis Assay.  Subconfluent HepG2,  MEF  or CHO  cell 
cultures  were  seeded into  12-well  plates  and incubated  in  assay 
medium for 30 min at 37°C.  In some of the wells,  the t:ells were 
preincubated either for 3 h at 37°C with heparinase or for 30 min 
at 37°C with heparin, anti-LP,.P or control antibodies, GST-R.AP 
or  lactoferrin  at  the  same  concentrations  indicated  for  the  cell 
binding assay, iLadiolabeled CS protein was added at a final con- 
centration of 4 nM and the incubation continued at 37°C for 0--6 h. 
In some experiments,  the lysosomal protease activity was inhib- 
ited by 0.1  mM chloroquine  (36).  To determine the amount of 
internalized protein (24), the cells were washed 5 ×  with PBS and 
then treated with 0.5 mg/ml trypsin, 5 mM EDTA, and 0.5 mg/ 
ml proteinase K in PBS, pH 7.4 (37), to remove cell surface-asso- 
ciated ligand. The cells were then pelleted and the cpm measured 
"by liquid scintillation counting. 
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were distinguished in subconfluent CHO-K1, CHO pgsA or wild- 
type, LP.,P-deficient,  LDLP,-deficient,  or LRP/LDLP.,-deficient 
MEF cells as described (8). Heparinase was added at a concentra- 
tion of 10 mU/ml for 3 h before addition of 5  ×  104 P.  berghei 
sporozoites  per  well  (8). Anti-LP,  P  antibodies  (10  la,  g/ml)  or 
GST-RAP  (500  lzg/ml) were added 30  min before and during 
co-cultivation with the sporozoites for 1 h. 
EEF Development Assay.  HepG2  cells were  cultivated  and 
EEF  immunolabeled as  described  (2). Heparinase plus  hepariti- 
nase were added at a concentration of 50 mU/ml each for 3 h be- 
fore  addition  of 1  ×  105  P.  berghei sporozoites per well.  GST- 
RAP (500 ~g/ml) was added 30 min before the parasites. 
Immunoelectron Microscopy.  Subconfluent  HepG2  cells were 
incubated for 2 h  at 4°C with  12.8 Izg/ml CS27IVC  in RPMI 
1640  medium, incubated  for  up  to  8  h  at  37°C,  embedded in 
Lowicryl K4M (Ted Pella Inc., 1Ledding, CA) and sectioned with 
an R.MC MT-7 ultramicrotome. Thin sections were sequentially 
labeled  with  10  p~g/ml mAb  2A10  and  PAG10  and  examined 
with a Zeiss EM 910 electron microscope. 
Immunofluorescence.  HepG2  cells were allowed to  internalize 
12.8  Izg/ml CS27IVC  for  4  h  at  4°C,  washed,  and  incubated 
for up to 8 h at 37°C. After fixation, the specimens were sequen- 
tially labeled with  10 btg/ml mAb 2A10 and GAM-FITC.  In an- 
other set of experiments, 40  i.zg/ml DAMP  were added for the 
last  2  h  of the  incubation  time.  The  internalized  DAMP  was 
stained with anti-DNP-TX (31). The specimens were examined 
with an inverted Nikon Diaphot microscope equipped with a Sa- 
rastro 2000 laser confocal scanning system (Molecular Dynamics, 
Sunnyvale, CA). 
Autoradiography.  Iodinated CS27IVC at a concentration of 10 
nM was added to subconfluent HepG2 or CHO-K1  cells grown 
on Lab-Tek tissue culture slides (Nunc, Naperville, IL) for 1, 4, 
12,  or 24 h. The cells were washed, fixed with methanol, coun- 
terstained with 0.1% Evans blue and the slides coated with Hy- 
percoat  EM-1  photographic  emulsion  (Amersham).  The  silver 
grains  in  the  photographic  emulsion  of autoradiography  speci- 
mens were visualized  in the reflection mode of the confocal mi- 
croscope. 
Results 
The  CS  Protein  Binds  to  both  Cell Surface Heparan  Sulfate 
Proteogtycans and LRP.  To  investigate  the  possibility  of a 
dual  interaction  of  recombinant  CS  protein  with  both 
HSPGs  and  LRP,  we  performed  binding  studies  using 
three  different  cell  types:  (a)  HepG2  cells,  which  possess 
HSPGs,  LRP,  and the LDLR  on their surface (24, 38),  (b) 
mutant  CHO  cell lines that  express LRP  and  the  LDLR, 
but are deficient in heparan sulfate biosynthesis and therefore 
express  only  the  core  proteins  of proteoglycans  (32,  38), 
and (c) several MEF cell lines which express HSPGs but are 
defective in either LRP, the LDLR, or both receptors (33). 
HepG2 cells were incubated with iodinated recombinant 
CS  protein  either in  the  presence  of heparin  to  compete 
with  the  host  receptor or after treatment of the  cells with 
heparinase to remove cell surface heparan sulfate. Both he- 
parin and heparinase treatment inhibited the binding of re- 
combinant  CS  protein in a  concentration-dependent fash- 
ion to a maximum of 85.8 and 71.4%, respectively (Table 1). 
When  HepG2  cells were incubated with  recombinant CS 
protein  in  the  presence  of a  polyclonal  anti-LRP  lgG,  a 
concentration-dependent  inhibition  of  the  CS  protein 
binding was observed to  a maximum of 64.2%  (Fig.  1 A). 
When  HepG2  cells  were  pretreated  with  heparinase  and 
then incubated with  recombinant CS  protein in  the pres- 
ence  of anti-LRP,  the  inhibition  reached  a  maximum  of 
98.4%, whereas a control antibody had no effect (Fig. 1 A). 
We then used GST-RAP  in combination with the hepari- 
nase  treatment.  RAP  inhibits  the  LRP-mediated  binding 
and  endocytic  uptake  of  all  known  ligands  (19).  Here, 
GST-RAP alone inhibited the binding of recombinant CS 
protein to HepG2 cells in a concentration-dependent man- 
ner,  with  a  maximum  of 82.6%,  whereas  in  combination 
with heparinase treatment, GST-RAP yielded 93.4% inhi- 
bition (Table  1).  These data indicate that interference with 
either heparan  sulfate  or LRP  inhibits  the  binding  of CS 
protein to HepG2 cells and almost complete inhibition can 
be obtained when both molecules are blocked. 
To  ensure  the  complete absence  of cell surface heparan 
sulfate and to exclude possible nonspecific effects of the he- 
parinase treatment on surface molecules other than heparan 
sulfate,  we  utilized  CHO  pgsA  cells  that  are  deficient  in 
heparan  sulfate  (32).  Controls  were  wild-type  CHO-K1 
cells that synthesize normal HSPGs.  Both cell lines express 
LlkP  (39)  and GST-RAP  was used to block this receptor. 
CHO  pgsA  cells bind  only 45.5%  of the  recombinant CS 
protein  in  comparison to  CHO-K1  cells,  presumably due 
to  the  lack  of  heparan  sulfate.  GST-RAP  inhibited  the 
binding of recombinant CS  protein to  CHO-K1  cells in a 
concentration-dependent  manner  with  maximum  inhibi- 
tion  being 77.3%  (Fig.  1  B).  However,  with  CHO  pgsA 
cells,  GST-R.AP  inhibited  the binding of recombinant CS 
protein by 93.4%  (Fig.  1 B).  Similarly, anti-LP,_P inhibited 
CS binding to CHO-K1  cells to a maximum of 46.1%, but 
to  CliO  pgsA  cells  to  a  maximum  of 93.7%  (Table  1), 
whereas  a  control  antibody  was  ineffective  (not  shown). 
Lactoferrin reduced the binding of recombinant CS protein 
to both  CHO-K1  and pgsA ceils to  a similar degree (89.2 
and  94.8%,  respectively)  (Table  1).  All  three  competitors 
had  the  same  strong  inhibitory  effect  on  the  CS  protein 
binding  to  heparan  sulfate-deficient CHO  pgsA  cells,  but 
lactoferrin, which interacts in a dual mode with both hepa- 
ran sulfate and LILP (14, 34, 40-42), was a more potent in- 
hibitor  of the  binding  to  wild-type  CHO  cells  than  anti- 
LP,.P.  Moreover,  it  seems  that  RAP  may  have  interacted 
weakly with  CHO  cell surface  heparan  sulfate  and  there- 
fore exhibited an intermediate inhibitory effect. 
Heparinase treatment of wild-type  and LDLP,.-deficient 
MEF  cells maximally reduced the binding by  only 35  and 
49%, respectively (data not shown). This contrasts with the 
results  obtained  by heparinase treatment of LRP-deficient 
MEF ceils which inhibited the binding of recombinant CS 
protein  in  a  concentration-dependent  fashion  by  up  to 
84%.  Thus  the vast majority of the receptor interaction of 
CS protein on the cell surface is mediated by LRP and not 
the LDLP,.. 
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Percent 
Cell type  Inhibitor  Concentration  Bound cpm  inhibition  P Value 
mean  ±  SD 
Binding* 
HepG2  none 
heparin  100 p~g/m] 
HepG2  none 
Hase  10 mU/ml 
HepG2  none 
RAP  150 btg/ml 
HepG2  none 
Hase +  RAP  150 ~g/ml 
CHO-K1  none 
lactoferrin  400 btg/ml 
CHO pgsA  none 
lactoferrin  400 t*g/ml 
CHO-K1  none 
anti-LRP  10 I~g/ml 
CHO  pgsA  none 
anti-LRP  10 I~g/ml 
Internalizations 
HepG2  none 
Chloroquine  0.1 mM 
HepG2  none 
RAP  150 btg/ml 
HepG2  none 
Hase +  RAP  150 ~g/ml 
CHO-K1  none 
anti-LRP  10 btg/ml 
CHO pgsA  none 
anti-L1LP  10 btg/ml 
CHO-K1  none 
lactoferrin  400 txg/ml 
CHO pgsA  none 
lactoferrin  400 I~g/ml 
11056.8  ±  1126.4  0 
1564.7  ±  173.2  85.8  0.007130 
11281.2  ±  872.9  0 
3231.6  ±  270.8  71.4  0.006384 
7182.4  ±  1445.1  0 
1253.1  ±  275.4  82.6  0.029425 
8339.9  ±  65.1  0 
545.7  ±  291.2  93.4  0.000921 
7513.5  ±  924.8  0 
810.4  ±  807.2  89.2  0.016358 
3862.6  ±  969.2  48.6  0.061207 
390.2  ±  411.7  94.8  0.009948 
6768.2  ±  230.4  0 
3653.4  ±  345.2  46.1  0.008760 
4418.0  ±  194.6  34.7  0.008132 
429.1  ±  34.7  93.7  0.000675 
6463.9  ±  332.1  0 
8949.6  ±  227.4  -38.5  0.012860 
6732.3  ±  1293.1  0 
1810.9  ±  678.3  73.1  0.009898 
7327.2  ±  348.5  0 
847.9  ±  304.7  88.4  0.007850 
5576.9  ±  204.2  0 
761.2  ~  195.9  86.4  0.001722 
4060.9  ±  210.1  27.2  0.018166 
528.4  ±  80.6  90.5  0.000944 
7310.5  ±  1692.6  0 
103.4  ±  39.9  98.6  0.026501 
3368.2  ±  468.7  53.9  0.086548 
435.1  ±  209.8  94.1  0.029417 
*Subconfluent HepG2 cells were preincubated for 30 min at 4°C with or without 0-150 ~g/ml GST-R.AP or Hase plus GST-RAP (10mU/ml + 
0-150 mg/ml). The heparinase treatment (0-10 mU/ml) was performed for 3 h at 37°C. CHO cells were treated with 0-10 ~g/ml anti-LRP or 
0-400 Ixg/ml lactoferrin. 125I-CS protein was then added at a concentration of 4 nM and the incubation continued at 4°C for another 2 h. Cell sur- 
face binding was determined by liquid scintillation counting. 
*12sI-CS protein was added to subconfluent HepG2 cells at 4 nM after a 30-min preincubation period with or without 0-150  p~g/ml GST-RAP, 
Hase plus GST-R.AP (10 mU/ml +  0-150 b~g/rnl) and to CHO cells after preincubation with anti-L1LP  or lactoferrin. The incubation was then 
continued for 3 h at 37°C before addition of other inhibitors or iodinated CS protein. Chloroquine was added to some of the wells during the inter- 
nalization period to prevent lysosomal  degradation. Cell surface-bound ligand was then proteolytically removed and internalized cpm measured by 
liquid scintillation counting. The values represent the mean of duplicate determinations +  SD.  P values were calculated using an independent equal 
variance t test. Shown are the results of one representative of duplicate experiments performed independently. 
Taken together, these binding studies indicate that block- 
age of either the HSPGs  or LRP  singly results in partial in- 
hibition  of  the  binding  of  recombinant  CS  protein, 
whereas  simultaneous  blockage  of both  HSPGs  and  LRP 
abolishes the interaction nearly  completely.  These binding 
studies  suggest that:  (a)  the  CS  protein interacts with both 
cell surface  heparan sulfate and LP, P  and  (b)  no additional 
receptors appear to be required for binding. 
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Figure  1.  Heparan sulfate proteoglycans and LRP mediate the cell surface 
binding of iodinated recombinant CS protein.  (A) Anti-LRP IgG (el-LRP) 
inhibits  the  CS  protein  binding  to  HepG2  cells  by 64%,  whereas anti- 
LRP in combination with heparinase pretreatment (10 mU/ml) results in 
98%  inhibition.  A  control  IgG is ineffective.  Subconfluent cell cultures 
were pretreated for 3 h at 37°C with increasing concentrations of hepari- 
nase  (Hase)  and/or  preincubated  for  30  rain  at  4°C  with  increasing 
amounts of inhibitor, lodinated CS271VC at a final concentration of 4 nM 
was  then  added  and  the  incubation  continued  for  another  2  h  at  4°C. 
Cell-associated radioactivity was determined by liquid scintillation count- 
ing.  The  indicated  values  represent  the  mean  of duplicates  +  SD.  (B) 
GST-RAP  inhibits  the  binding  of iodinated  CS  protein  to  wild-type 
CHO-K1  cells by 77% and to heparan  sulfate-deficient CHO pgsA cells 
93%. Shown is one of two independent experiments for each experimen- 
tal condition. 
LRP Mediates  the Endocytic  Uptake of Recombinant CS Pro- 
tein.  HepG2  cells  were  incubated  with  12sI-CS  protein 
and the amount of internalized CS protein determined after 
proteolytic  removal  of cell  surface-associated  ligand.  The 
accumulation  of intracellular CS protein reached its maxi- 
mum  after  3-5  h  and  decreased  subsequently  (Fig.  2  A). 
This decrease was completely prevented in the presence of 
0.1  mM  chloroquine  (Table  1),  which  interferes  with  in- 
tracellular protein degradation by blocking iysosomal acidi- 
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fication  (35).  When  binding  of CS  protein  to  cell surface 
HSPGs was selectively inhibited either by heparinase diges- 
tion or by competition with heparin, the uptake of recom- 
binant  CS  protein  was  inhibited  by  70.4  and  92.7%,  re- 
spectively  (Fig.  2  A).  Blockage  of the  interaction  of CS 
protein  and LRP on  the HepG2  cell surface by increasing 
amounts of anti-LRP inhibited the uptake of recombinant 
CS  protein  in  a  concentration-dependent  manner  to  a 
maximum of 71.5%, while a control antibody was inactive 
(Fig. 2/3). If the cells were pretreated with heparinase, anti- 
LRP antibody blocked endocytosis of CS protein by up to 
98.6%  (Fig. 2 B).  Taken together, these results suggest that 
in  HepG2  cells,  both  HSPGs  and  LRP  are  important  for 
the endocytosis of recombinant CS protein.  The complete 
inhibition  of CS  protein  uptake  after  elimination  of the 
two molecules also suggests that no other receptors  (3,  43) 
are required. 
Mutant  CHO  cell  lines  were  used  to  exclude  possible 
nonspecific  effects  on  the  HepG2  cells.  In  comparison  to 
the wild type CHO-K1  cells, endocytosis of CS protein by 
heparan  sulfate-deficient  CHO  pgsA  cells was reduced by 
46.4%  (Fig.  2  C).  When  LRP  was blocked  on  CHO-K1 
cells by GST-RAP  (Fig.  2  C)  or anti-LRP  (Table  1),  the 
internalization of recombinant CS protein was inhibited by 
85.3%  and  86.4%,  respectively.  When  CHO  pgsA  cells 
were exposed to GST-RAP  or anti-LRP,  endocytosis was 
inhibited by more than 90% in both cases. Thus, compared 
to HepG2 cells, GST-RAP and anti-LRP exhibited a some- 
what  stronger  inhibitory  effect  on  the  CS  protein  uptake 
by CHO-K1  cells indicating that CHO  cells rely more on 
LRP for the binding of CS protein than on heparan sulfate 
compared to HepG2 cells. Lactoferrin, which binds to both 
LRP  and  cell surface  heparan  sulfate,  blocked  endocytosis 
by  more  than  94%  independently  of the  CHO  cell  type 
(Table  1). 
The  relative  roles  of LRP  and LDLR were  analysed in 
MEF  cell  lines.  Wild-type  MEF  cells  expressing  both  re- 
ceptors exhibit an endocytosis curve with a maximum in- 
tracellutar accumulation of CS protein at 5 h  (not shown). 
Compared  to  wild-type  cells,  LRP-deficient  and  LRP/ 
LDLR-deficient double mutant MEF cells both showed no 
significant  uptake  of CS  protein  (92.9  and  94.8%  inhibi- 
tion, respectively; data not shown)  emphasizing the crucial 
role of LRP in this process.  However,  uptake of recombi- 
nant  CS  protein  by LDLR-deficient  cells was reduced  by 
35.1% suggesting that, although the LDLR receptor is not 
obligatory for the internalization of CS protein, it may sup- 
port the action of LRP. Degradation of cell surface heparan 
sulfate of wild type MEF cells by heparinase caused a 53.9% 
inhibition  of uptake  at  the  highest  enzyme  concentration 
(data  not  shown)  suggesting  that  the  heparan  sulfate  of 
MEF cells does facilitate endocytotic uptake of CS protein 
to a similar degree as for CHO cells where heparinase treat- 
ment inhibits by "-'50%. This effect is lower, however, than 
in  HepG2  cells where  the  same  treatment  inhibits  uptake 
by  ¢'-'70%. When  HSPGs  were  eliminated  by  heparinase 
pretreatment of MEF mutant cell lines lacking either LRP 
or LRP/LDLR,  we found 93  and 95% inhibition,  respec- A 
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tively (data not shown). Thus, similarly to the above results 
with  HepG2  and  CHO  cells,  the  elimination of  both 
HSPGs  and L1KP as  CS  protein binding sites  completely 
abolished the  endocytotic uptake of the  CS  protein.  The 
LDL1K appears to play only a minor role in these events. 
The  CS  Protein Binds  with  High  Affinity and Specificity to 
LRP.  Iodinated CS protein was allowed to react with pu- 
rified human LRP in a solid phase assay in the presence of 
increasing concentrations of competitors: either unlabeled 
CS protein (Fig. 3 A) or GST-RAP (Fig. 3/3). The result- 
ing curve represents the best fit to a single class of sites and 
the apparent K a of 4.9 nM suggests a specific ligand-recep- 
tor interaction. GST-RAP inhibited the interaction of the 
iodinated CS protein with purified LRP with a resulting K i 
of 9.5 nM. No binding ofiodinated CS protein occurred in 
control wells coated with BSA (Fig. 3, A  and B). These re- 
sults suggest a specific receptor-ligand interaction between 
recombinant CS protein and purified LRP. The binding of 
iodinated CS protein the surface of HepG2 cells was inhib- 
ited by unlabeled CS protein or GST-RAP in a concentra- 
tion-dependent and saturable fashion (Fig. 3  C).  The iodi- 
nated  CS  protein  was  displaced  by  cold  ligand with  an 
apparent K d of 0.4 nM (Fig. 3  C)  and by GST-RAP with 
an apparent K i of 0.8 nM (Fig. 3  D), which is in the same 
order of magnitude as the RAP-mediated displacement of 
tissue-type  plasminogen  activator  from  the  surface  of  rat 
hepatoma cells (40). 
Internalized  CS Protein Enters the Endocytotic Pathway and 
Is Degraded in Lysosomes.  When HepG2  cells  were  incu- 
bated with recombinant CS protein at 4°C, the CS protein 
was found to be restricted to the cell surface microvilli (not 
shown). When the cells were incubated at 37°C for up to 8 h, 
the CS protein gradually disappeared from the cell surface 
and  entered  cytoplasmic vesicles  (Fig.  4  A).  DAMP  was 
then used as  a  marker for acidic organelles (31)  to  deter- 
mine  the  nature  of  the  CS  protein-containing vesicles. 
Double labeling studies in combination with confocal colo- 
calization revealed that the  CS protein had  entered lysos- 
omes (Fig. 4, B and C). 
Microautoradiography was used to determine the intrac- 
ellular, long-term fate of internalized 125I-labeled  CS pro- 
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Figure 2.  Heparan  sulfate proteoglycans and LIKP mediate the endo- 
cytic uptake of iodinated recombinant  CS protein. Subconfluent  cell cul- 
tures were incubated at 37°C with iodinated CS27IVC at a final concen- 
tration of 4 nM in the presence various  inhibitors.  Internalized  CS protein 
was determined after proteolytic treatment of the cells to dissociate sur- 
face-bound CS protein. (A) Time course of the internalization  of iodi- 
nated CS protein (CSP) into HepG2 cells. The intracellular  accumulation 
of CS protein reaches a peak at 3-6 h and is inhibited by pretreatment of 
the cells with 10 mU/nfl heparinase or in the presence of 10 I,  Lg/ml hep- 
arin. (B) At 3 h, the endocytic uptake of recombinant CS protein into 
HepG2 cells is inhibited by anti-LRP (oe-LRP) by a maximum of 72%. 
After pretreatment of the cells with 10 mU/ml heparinase, anti-LRP in- 
hibits the uptake by a maximum of 99%. (C) After a 3-h incubation 
period, GST-RAP inhibits the uptake of recombinant CS protein into 
wild-type CHO-K1 cells  by a maximum of 85% and into heparan sulfate- 
deficient CHO pgsA cells by 95%. Note that in the absence ofinhibitors, 
the endocytic  uptake of CS protein into CHO pgsA cells is only ~50% of 
the CHO-K1-  cells, 
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Figure 3.  (A and B) Iodinated 
CS  protein  binds  specifically 
to  purified  LR.P.  Iodinated 
CS271VC  at  a  final  concentra- 
tion of 2  nM  was  incubated  at 
4°C  with LRP- or BSA-coated 
wells  in  the  presence  of 0-200 
nM unlabeled  CS protein (A) or 
0-200  nM  GST-RAP (B). The 
amount  of bound  iodinated  CS 
protein was determined  by liquid 
scintillation  counting  and  the 
data analyzed using the program 
LIGAND.  The rindicated  values 
represent  the mean of duplicates 
+  SD. The curves represent  the 
best-fit  to a single class of bind- 
ing sites with a K  d of 4.9 nM for 
CS  protein  and  a K  i of 9.5  for 
GST-RAP.  No  CS  protein 
binding  was  observed  to  the 
BSA-coated  wells.  (C)  and  (D) 
lodinated recombinant  CS  pro- 
tein binds to LP,.P on the surface 
of  HepG2  cells. Subconfluent 
HepG2  cells  were  incubated 
with iodinated  CS27IVC at a fi- 
nal concentration  of 4 nM in the 
presence of either 0-400 nM un- 
labeled ligand (A)  or GST-RAP 
(/3)  for  2  h  at  4°C  and  the 
amount  of  cell  surface-bound 
12sI-CS27IVC  measured.  The 
radiolabeled  CS  protein  is  dis- 
placed by cold ligand with an ap- 
parent  K  d of ~0.4  nM  and  by 
GST-RAP with an  apparent  K, 
in  the  range  of 0.8  nM.  Each 
point represents the mean of du- 
plicate  determinations.  The fig- 
ure shows  one of two indepen- 
dently performed experiments. 
tein. This approach was necessary since available antibodies 
recognize  only  the  repeat  region  and  neither  the  COOH 
or NH 2 terminus  of the  CS protein  would  have been  de- 
tected  by  immunolabeling.  After  24  h  of incubation,  the 
iodine  label  had  redistributed  from  an  initially  uniform 
staining  of the peripheral  cytoplasm  (corresponding  to  en- 
docytosis  vesicles)  to  a juxtanuclear  localization  (Fig.  4  D) 
suggesting that  the  CS protein was  confined to  the lysoso- 
mal compartment  of the  cell.  Taken  together with  the  ef- 
fect of chloroquine,  these  data  show that  recombinant  CS 
protein  remains  confined  to  the  endosomal  compartment 
of the cell and is lysosomally degraded. 
Both HSPGs and LRP Are Required for P.  berghei Sporozo- 
ite Invasion.  Next,  we  investigated  the  role  of both  LRP 
and LDLR  in the invasion of host cells by P. berghei sporo- 
zoites using mutant MEF cells deficient in either LP,.P or in 
both  LRP  and  LDLR.  Invaded  sporozoites  were  distin- 
guished from attached parasites by double labeling (8).  He- 
parinase  treatment of wild-type MEF  cells had some effect, 
i.e.,  18.3-23.9%  inhibition,  on  parasite  entry  (Table  2). 
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Sporozoite invasion ofLRP-deficient MEF cells was inhib- 
ited by  31.1%  in  comparison  to  the  wild-type  MEF  cells. 
Prior  heparinase  treatment  of these  LRP-deficient  MEF 
cells lead to a  marked  60.5%  inhibition  of sporozoite inva- 
sion.  Likewise, invasion of LRP/LDLR-deficient  cells was 
inhibited by 45.9% compared to wild type cells and hepari- 
nase treatment increased the inhibition to 72.4%  (Table 2). 
These data suggest that sporozoite invasion is mediated pre- 
dominantly  by  LRP  in  concert  with  HSPGs  and  perhaps 
supported  to a minor extent by the LDLR. 
P.  berghei sporozoite  invasion  of CHO-K1  and  heparan 
sulfate-deficient CHO  pgsA cells was inhibited by lactofer- 
rin  by  more  than  60%  (Fig.  5  A).  Notably,  lactoferrin 
blocks  LRP  and  interferes  also  with  the  HSPG-mediated 
CS  protein  binding  on  the  CHO-K1  cells  (14)  thus  ex- 
plaining  the  equally strong  effect on  invasion  of both  the 
wild-type and the heparan sulfate-deficient cells. GST-RAP, 
which  blocks  predominantly  LRP  and  appears  to  interact 
less  strongly  with  CHO  cell surface  HSPGs  than  lactofer- 
tin,  inhibited  sporozoite  invasion  of  CliO-K1  cells  by Figure 4.  Recombinant CS protein enters the lysosmal compartment. (A) Subconfluent HepG2 cells were incubated for 2 h  at 4°C with CS27IVC, 
washed, incubated for 10 rain at 37°C, fixed, and embedded in Lowicryl K4M. CS protein is found associated with microvilli (MV)  on the cell surface 
and internalized in vesicles (arrow) as detected by sequential immunolabefing with mAb 2A10 and PAG10. M, mitochondrium; N, nucleus. (B and C) Af- 
ter a 4-h incubation period, HepG2 cells contain CS protein-positive vesicles (C, arrows). By confocal microscopy, most of the vesicles that contain en- 
docytosed CS27IVC colocalize with DAMP-positive acidic organelles (B, arrows) suggesting that the CS protein had entered lysosomes. CS27IVC in cry- 
osections of HepG2 cells was labeled with mAb 2A10 and GAM-FITC, DAMP was detected with anti-DNP-TX. N, nucleus. (D)  HepG2 cells were 
incubated for 24 h with iodinated CS protein and prepared for microautoradiography. Evans blue-stained specimens were scanned by confocal micros- 
copy and the localization of the silver grains visualized in relation to the cellular compartments. The distribution of the silver grains (arrows) suggests the 
targeting of the internalized CS27IVC to ajuxtanuclear compartment. N, nucleus. Bars: (A) 0.2 ~m; (C and D)  10 ~m. 
1706  Dual Interaction of the Malaria Circumsporozoite Protein Table 2.  Inhibition of PIasmodium berghei Sporozoite Invasion In  Vitro 
Cell type  Inhibitor 
Percent 
Invaded Sporozoites  Inhibition  P Value 
MEF/wt 
MEF/LRP-de£ 
MEF/wt 
MEF/LRP/LDLR-defi 
CHO-K1 
CHO pgsA 
CHO-K1 
CHO pgsA 
mean +  SD 
none  253.5  -+  25.0  0 
Hase  193.0  _  12.7  23.9  0.009642 
none  174.7  _+  15.0  31.1  0.008084 
Hase  100.0  +  30.7  60.5  0.000338 
none  185.0 +  67.2  0 
Hase  151.0 ___ 25.9  18.3  0.444994 
none  100.0 +_  14.5  45.9  0.074696 
Hase  51.0  +  13.8  72.4  0.014472 
none  483.8  _+ 53.3  0 
anti-LP, P  325.3  +  48.3  32.8  0.008812 
none  290.5  ___ 30.0  39.9  0.001553 
anti-LRP  204.5  +  40.9  57.7  0.000363 
none  345.5  +  28.8  0 
RAP  229.8 +  22.5  33.5  0.001539 
none  177.5  _+ 20.0  48.6  0.000166 
RAP  85.8  +  7.0  75.2  0.000005 
Wild-type, LRP-deficient or LRP/LDLR-deficient MEF cells or CHO-K1  or psgA cells were incubated for 2 d to subconfluency.  The MEF cells 
were pretreated with or without with 10 mU/ml heparinase (Hase) and cocultivated with P. berghei sporozoites for 1 h. The CHO cells were cocul- 
tivated with P. berghei sporozoites for 1 h in the presence or absence of 10 I,g/ml anti-LP,.P IgG or 500 mg/ml GST-RAP. The cultures were then 
fixed and double labeled to distinguish between extracellular and intraceltular sporozoites. The indicated'values represent the mean number of sporo- 
zoites counted in entire 4 wells +  SD. P values were calculated using an independent equal variance t test. Shown are the results of one representa- 
tive of duplicate experiments performed independently. 
33.5%,  but invasion  of CHO  pgsA cells by a maximum of 
75.2%  (Table  2).  When  anti-LRP  was  used  to  selectively 
block LP,.P, sporozoite invasion of CHO  pgsA cells was in- 
hibited by  57.7%,  whereas  under  the  same  conditions,  the 
wild-type cells exhibited only 32.8% inhibition  (Table 2). 
HepG2  cells  support  the  intracellular  differentiation  of 
malaria  parasites  from  the  sporozoite  to  the  mature  exo- 
erythrocytic form (EEF) stage, whereas in all other cells, in- 
cluding  MEF  and  CHO  cells,  parasite  development  is  ar- 
rested  shortly  after  sporozoite  invasion.  Development  of 
P.  berghei  EEF  in  HepG2  cells  that  had  been  pretreated 
with  heparinase  plus  heparitinase  was  inhibited  only  by 
17%  (Fig.  5  B),  corroborating  our previous  data  (8).  Like- 
wise,  GST-RJkP inhibited EEF development only by 21%. 
However,  GST-RAP  in  combination  with  removal  of 
HSPG exhibited a strong 65% inhibitory effect. These  data 
demonstrate  clearly  the  relevance  of the  dual  CS  protein 
binding sites during the interaction  of sporozoites with  the 
host cell. 
Discussion 
The major implication of this work is that malaria sporo- 
zoites  depend on the dual binding to the low density LRP 
and cell surface HSPGs for host cell invasion.  This  conclu- 
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sion is based on the finding that, firstly, recombinant  P.fal- 
ciparum  CS  protein  binds  with  high  affinity  and specificity 
to  purified  human  LP,  P,  an  interaction  that  can  be  inhib- 
ited by a protein known to block the receptor function  of 
LP,.P,  i.e.,  RAP.  Secondly,  binding  and  internalization  of 
recombinant  CS protein into HepG2,  CHO,  or MEF  cells 
was  virtually  eliminated  by  the  combined  inhibition  of 
heparan  sulfate and LRP.  Thirdly,  the same result was ob- 
tained  whether  competitors  of the  interaction  or  mutant 
cells deficient in the participating molecules were used or if 
the  cells  were  enzymatically  pretreated.  Moreover,  elimi- 
nation of only heparan sulfate or only LP,  P  consistently re- 
suited only in partial inhibition of binding or endocytosis of 
recombinant  CS  protein  and  had  only  a  minor  effect  on 
sporozoite  invasion.  Finally,  the  strong inhibitory  effect of 
the  combined  blockage  of HSPGs  and  LRP  on  P.  berghei 
sporozoite  invasion  in vitro  suggests  that  this  dual  interac- 
tion  of  the  CS  protein  represents  the  major  molecular 
mechanism  for  host  cell  entry  used  by  this  apicomplexan 
parasite. 
The cell surface binding properties of the CS protein have 
a  striking  similarity  to  those  of apo  E-enriched  [3-VLDL, 
which  bind  initially  in  an  HSPG-mediated  process  to  the 
liver  and  to  HepG2  cells  (12-14).  Subsequently,  these 
13-VLDL  are  thought  to  be  transferred  to  LRP  and  inter- A 
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Figure 5.  P. berghei sporozoites depend on the dual binding to heparan 
sulfate and LRP during host cell invasion. (A) Wild-type CHO-K1 or hepa- 
ran sulfate-deficient CHO pgsA cells were co-cultivated with P.  berghei 
sporozoites for 1 h at 37°C in the absence or presence of increasing con- 
centrations oflactoferrin  (L, concentrations in p~g/ml) or transferrin (7). 
Lactoferrin inhibits sporozoite invasion into  both CHO-K1  and pgsA 
cells in a concentration-dependent fashion to a maximum of 71 and 60%, 
respectively. Transferrin has no effect. Intra- and extracellular parasites 
were  distinguished by double labeling. Each bar  represents the  mean 
number of invaded sporozoites counted in four wells _+ SD. (/3) HepG2 
cells were cocultivated with P.  berghei sporozoites and EEF detected by 
sequential immunolabeling with mAb 2E6 and goat anti-mouse peroxi- 
dase after 48 h (control). HepG2 cells in other wells were either after pre- 
treated with heparinase and heparitinase (50 mU/ml each), in the pres- 
ence of 500  p~g/ml GST-RAP or both.  Each bar represents the mean 
number of EEF counted in four wells +  SD. Note that whereas the en- 
zyme treatment alone or the blockage by RAP of LRP alone resulted 
only in  19  and 21% inhibition,  respectively. However,  elimination of 
both HSPGs and LFkP as CS protein binding sites inhibits sporozoite in- 
vasion by 65%. 
nalized in a RAP-sensitive process (15). These and our cur- 
rent  findings  strongly  support  the  notion  that  malaria 
sporozoites,  by  recognizing  LRP  in  combination  with 
liver-specific heparan  sulfate,  utilize  an  established meta- 
bolic pathway of the mammalian host to selectively invade 
hepatocytes. 
The binding of the CS protein to purified LIKP is char- 
acterized by high affinity and is in the same range as the af- 
finity of other LRP ligands (24, 36, 37). However, the data 
obtained for the interaction of the CS protein with the sur- 
face of HepG2 cells did not fit a one or two-site model us- 
ing the program LIGAND (35) as might be expected since 
we used an aggregated preparation of recombinant CS pro- 
tein  for  these  studies.  A  more  complex  interaction  may 
therefore have occurred on the cell surface involving mul- 
tiple CS  protein molecules,  LlkPs  and/or  heparan  sulfate 
chains,  much  like  that  which  would  occur  between  a 
sporozoite and a host cell. Nevertheless, an estimate of the 
apparent dissociation constants suggests that the overall af- 
finity of the  CS  protein  to  the  surface  of HepG2  cells is 
"-q0  times higher than to purified LRP.  This is in agree- 
ment with the ~10-fold increased affinity between  bFGF 
and the growth factor receptor 1 in the presence ofheparin 
(44, 45). Malaria sporozoites are covered by a dense surface 
coat of CS protein and it is probable that the host cell affin- 
ity of these relatively large microorganisms exceeds greatly 
the affinity values presented here. 
The  basic amino  acid motifs in the  conserved regions I 
and II-plus of the CS protein may bind to  highly sulfated 
heparin-like  oligosaccharides  in  heparan  sulfate  (unpub- 
lished data) and also to the negatively charged SDE (serine- 
aspartate-glutamate) motifs in  the  ligand binding domains 
of L1KP and the LDLR  (44).  The  unique heparin-like na- 
ture  of the  liver-specific heparan  sulfate  (7)  may mediate 
the initial arrest of the CS protein in this organ and our ob- 
servation of the larger contribution to the CS protein bind- 
ing  of HepG2  cell  heparan  sulfate  ('°70%)  compared  to 
that from CHO  or MEF cells ("-~45 or ~35%,  respectively) 
supports this notion.  HepG2  cells are transformed hepato- 
cytes and in contrast to heparan sulfate from human skin fi- 
broblasts and bovine kidney tissue, the distal two-thirds of 
rat liver heparan sulfate chains are clearly heparin-like (7). 
Basic oligopeptide motifs have also been implicated in the 
binding  of lactoferrin  and  apo  E  to  LIKP  (11,  47,  48). 
Significantly,  these  motifs  resemble  the  clusters  of basic 
amino acids NH2-terminal from the conserved region I and 
within region II-plus of the CS protein both of which have 
been  implicated in host  cell binding and  sporozoite inva- 
sion  (2,  49,  unpublished  data);  These  considerations  and 
our finding that lactoferrin inhibits the binding of the  CS 
protein in the absence of cell surface heparan sulfate to the 
same degree as the universal LRP-inhibitor RAP (34) sug- 
gest the possibility that  the  CS  protein binds to  the  same 
site on LRP as apo E  and lactoferrin. 
We show here that malaria sporozoites utilize the inter- 
action beween  the  CS protein and a  dual receptor system 
for host cell binding. Similarly, P. falciparum-infected  eryth- 
rocytes with the parasite-derived variant antigen PfEMP-1 
bind  to  CD36,  thrombospondin  and  ICAM-1  (50,  51). 
Thus,  like many other microorganisms (see references in 8), 
Plasmodium  has developed multiple recognition strategies to 
guarantee its survival in the mammalian host. After the ini- 
tial binding event, however, malaria sporozoites appear not 
to depend on the endocytic machinery of the mammalian 
cell for  invasion,  since  shortly  after  entry,  sporozoites lie 
free in the cell and release considerable amounts of CS pro- 
tein directly into the cytosol (52). Thus, in contrast to solu- 
1708  Dual Interaction of the Malaria Circumsporozoite Protein ble  recombinant  CS  constructs,  which remain restricted to 
the  endocytic  compartment,  malaria  sporozoites  possess 
mechanisms  to  cross  mammalian  membranes  and  thereby 
enable  the  CS  protein  to  fulfill  possible  intracellular  func- 
tions  after  its  association  with  ribosomes  of the  host  cell 
(52). 
Although  elimination  of both L1KP and HSPGs was suf- 
ficient to completely abolish cell surface binding of recom- 
binant  CS protein,  additional  ligand  receptor pairs may be 
involved  in  sporozoite  invasion.  Blockage  or  absence  of 
LRP  and  HSPGs  caused  only  a  60-80%  inhibition  of 
sporozoite invasion.  One explanation is that the multimeric 
high-avidity  sporozoite  /  host cell  interaction  may not  ef- 
fectively be inhibited with monomeric  competitors.  Alter- 
natively,  native  CS  protein  expressed  on  the  surface  of 
sporozoites and/or other parasite  surface molecules such as 
the thrombospondin-related  adhesive protein  (TRAP)  may 
contribute  to  the  host  cell  recognition  by  binding  to  the 
same  and possibly also  to  additional  receptors.  Support  for 
this  comes  from  the  finding  that  highly  sulfated  polymers 
such as fucoidan or dextran sulfate consistently yield an in- 
hibitory  effect  on sporozoite  invasion  in  the  range  of 80- 
90%  (3,  unpublished  data).  It is possible  that  these sulfated 
polymers block the CS protein  and TRAP  simultaneously, 
since  both  molecules  contain  region  II  plus-like  heparin- 
binding  motifs  (4,  53).  Moreover,  TRAP  contains  se- 
quences  homologous  to  the  ~2-integrin  A-type  domain 
superfamily (54) and it is conceivable that malaria sporozoi- 
tes use this molecule for the binding to  additional  host cell 
receptors.  Nevertheless,  the  molecule  that  is  expressed 
most  abundantly  on the  sporozoite  surface  is  the  CS  pro- 
tein  and  our  data  suggest  that  the  binding  to  LRP  and 
HSPGs represents the predominant interaction  during par- 
asite invasion. 
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